1 / 10

PANEL Presentation 4 October 2004 Dr Mark Heffernan CEO

PANEL Presentation 4 October 2004 Dr Mark Heffernan CEO. Opsona’s Rationale. Focused on the development of therapeutics and preventatives for a utoimmune and inflammatory diseases Biopharmaceutical Program : Two lead drugs: OPN-101: Preventative and therapeutic for autoimmune diseases

odette
Download Presentation

PANEL Presentation 4 October 2004 Dr Mark Heffernan CEO

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. PANEL Presentation 4 October 2004 Dr Mark Heffernan CEO

  2. Opsona’s Rationale • Focused on the development of therapeutics and preventatives for autoimmune and inflammatory diseases • Biopharmaceutical Program: • Two lead drugs: • OPN-101: Preventative and therapeutic for autoimmune diseases • OPN-201:Preventative and therapeutic for autoimmune diseases • Toll-Like Receptor (TLR) Program: in discussion with Pharma/Biotech re drug discovery agreement • Small molecules: including orally available molecules for treatment of immune-mediated diseases • Exclusive option agreement to future technology • Founded in March 2004 with three leading immunologists from Trinity College Dublin

  3. The Opsona Model • The Opsona model: • Mark Heffernan, the University and 3 Academics agree to pursue an idea for biotechnology start-up • Idea shows success and company in negotiations to raise ~€5m A-round finance • ALL WITHIN 9 MONTHS

  4. The Founders Dr Mark Heffernan (Co-Founder and CEO): • Senior management at Metabolic Pharmaceuticals Ltd and Antisense Therapeutics Ltd (Australia) – • R&D and BD background Dr Cormac Kilty (Chairman) • CEO Biotrin International • Chairman Irish BioIndustry Association Prof Kingston Mills (Co-founder and Director): • Professor of Experimental Immunology, TCD, • International reputation in Immune regulation • Product commercialisation with Elan and Chiron Prof Luke O’Neill (Co-founder and Director): • Director of the Biotechnology Institute, TCD • International expert in Toll receptor biology Prof Dermot Kelleher (Co-founder and Director): • Director Dept Clin Med. TCD, • Gastroenterologist/Clinical Trials Expertise, • Technology licensing to Chiron Corp

  5. Outstanding Science • Founders are international opinion leaders in basic and clinical research. • Over 500 papers - Nature, Science, J. Exp Med., JBC, Lancet, NEJM, Scientific American • Extensive industry collaborations • >€15m in funding and > 40 lab staff • Intellectual property and proprietary skills in immunomodulation - Hot area! • Two lead drugs – with proof of principle animal experiments established • Rich Pipeline of drugs and novel therapeutic approaches • Significant partnering interest from Pharma and Biotech companies

  6. Company Development

  7. The Model Flow-Chart November/December 2003: MH talks with three key academics December 15th 2003: TCD agrees to undertake feasibility study with MH January 2004: Feasibility Commences MH appoints Bus Dev Consultants February 2004: Receive €30k grant from EI (50% cost of study) Technology Assessment begins March 2004: Opsona Incorporates as a Pvt Ltd company in Ireland Business Plan commenced April 2004: Chairman appointed – Irish Industry Leader June 2004: BPlan complete, VC approached. MH attends major International Biotech Conference, meets with key Industry players

  8. The Model Flow-Chart July 2004: International VCs Approached Syndicate taking shape August 2004: Clinical plan commences – contract key clinicians and consulting companies Negotiations with TCD over License/Option commence October 2004: Development of investor syndicate Clinical plan complete December 2004: Close fundraising & commence operations

  9. Summary Opsona: • start-up company with: • world-leading technology • key scientific founders • rich pipeline • complete proof-of-principle animal experiemts with outstanding data with lead compound, OPN-101 • Clinical trial to commence in 2005 • Program to partner with Biotech/Pharma in 2004/2005 • To succeed: • Get to know everyone fast! • Surround yourself with experienced opinion leaders and advisors • Have story right before approaching VCs • Have access to enough funds for feasibility • Set tight milestones and deadlines

  10. Contact For investment and general enquiries contact: Dr Mark Heffernan, CEO Opsona TherapeuticsLtd, The O’Reilly Institute, Trinity College Dublin, Dublin 2 email: heffernan@opsona.com Ph:+353 (0) 876 434 766, Fax: +353 1 679 8039

More Related